Exelixis
NASDAQ:EXEL
$5.67
-$0.47
(-7.69%)
Quote as of 4:00 PM EST on 02/09/12
Related Resources
EXEL
vs. S&P 500
|
$5.67
-$0.47
(-7.69%)
|
|
| Today's Open | $6.22 |
|---|---|
| Previous Close | $6.14 |
| Daily Range | $5.63 - $6.25 |
| 52-Week Range | $3.94 - $12.82 |
| Market Cap | $735.06M |
| P/E Ratio | 87.71 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 2,665,804 |
| Average Daily Volume | 1,618,505 |
| Current FY EPS | $0.09 |
EXEL Information
| Description |
|---|
| A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. |
| Sector |
| Healthcare |
| Industry |
| Life Sciences Tools and Services |
News & Commentary
When Passing Your Clinical Trial Isn't Enough
2/9/2012 by DailyFinance
Can Amgen Convince Docs to Recommend Approval?
2/7/2012 by DailyFinance
1/31/2012 by DailyFinance
Make Money in Dynamic Biotech Stocks the Easy Way
1/26/2012 by DailyFinance
1/13/2012 by DailyFinance
4-Star Stocks Poised to Pop: Exelixis
1/10/2012 by DailyFinance
JPMorgan Confab Kicks Off Biotech 2012
1/5/2012 by Minyanville
1/5/2012 by DailyFinance
1/4/2012 by DailyFinance
12/30/2011 by DailyFinance
